Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Onpattro (patisiran), the gene-silencing drug from US biotech Alnylam, has been approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in Japan. 19 June 2019
Biotechnology
Boston, USA-based cell therapy developer Gamida Cell and Switzerland’s Lonza today announced that they have entered into a strategic manufacturing agreement. 19 June 2019
Biotechnology
Chinese cancer specialist BeiGene has entered into a second collaboration with SpringWorks Therapeutics, a spin-out from US pharma giant Pfizer. 18 June 2019
Biotechnology
Much of the dialogue surrounding Roche’s oncology drugs is currently about the big-selling products at the end of their patent life, but the company has provided a timely reminder that its new innovations are a big deal too. 18 June 2019
Biotechnology
Merck & Co has been granted a new label update for its immuno-oncology blockbuster, Keytruda (pembrolizumab), in metastatic small cell lung cancer (SCLC). 18 June 2019
Biotechnology
Having already backed out of an option on a Parkinson’s disease program in 2017, Sanofi Genzyme is now pulling further out of its collaboration with USA-based Voyager Therapeutics, as the companies yesterday announced a restructuring of their gene therapy relationship. 18 June 2019
Biotechnology
Tumor drug resistance specialist Deciphera Pharmaceuticals has inked a deal with Shanghai-based Zai Lab to advance the development and commercialization of ripretinib in China. 18 June 2019
Biotechnology
Belgian immunotherapies developer Imcyse today announces that it has raised 35 million euros ($39.5 million) in a Series B financing round and through other channels. Imcyse is a spin-off from Belgium’s Katholieke Universiteit Leuven (KUL). 18 June 2019
Biotechnology
At first glance, an observer might have predicted that shares in VBI Vaccines would have shot up based on the results of its PROTECT Phase III study, rather than to decline by more than 60% as they did on Monday morning. 17 June 2019
Biotechnology
Sino-American biotech BeiGene has been handed back rights to its investigational checkpoint inhibitor tislelizumab by New York’s Celgene. 17 June 2019
Biotechnology
AstraZeneca could be on course to gain another indication with Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor that already has accelerated US approval for mantle cell lymphoma (MCL). 17 June 2019
Biotechnology
CASI Pharmaceuticals has revealed it has signed a license agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas Cell Therapy, a China-based domestic company located in Tianjin City, China. 17 June 2019
Biotechnology
The global cell therapy market size is expected to reach a value of $7.92 billion by 2025, rising at a compound annual growth rate (CAGR) of 5.34% during the forecast period. 17 June 2019
Biotechnology
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
Biotechnology
US pharma giant Pfizer today announced that it will acquire Array BioPharma, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. 17 June 2019
Biotechnology
An oral presentation at the annual meeting of the European Congress of Rheumatology (EULAR) has detailed positive results from a Phase III study of brodalumab (KHK4827). 17 June 2019
Biotechnology
Today, at the 24th World Congress of Dermatology (WCD) taking place in Milan, Italy, US biotech firm Incyte (Nasdaq: INCY) presented 24-week data from its Phase II study evaluating ruxolitinib cream as a treatment for adult patients with vitiligo. 15 June 2019
Biotechnology
Indian drugmaker Sun Pharmaceutical Industries’ Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown. 14 June 2019
Biotechnology
Bimekizumab is a crucial pipeline drug for UCB – allowing the company’s to look beyond Cimzia (certolizumab pegol) in immunology – so each successful data read-out is a relief for the Belgian drugmaker. 14 June 2019
Biotechnology
Positive topline results from the Phase III PEMPHIX study show Rituxan (rituximab) compares favorably as a therapy for the rare, serious and potentially life-threatening condition pemphigus vulgaris (PV). 14 June 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze